What changed: Cancer of unknown primary, favourable subsets
Every dated change on the records linked to Cancer of unknown primary, favourable subsets, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
September 2026 · 1
2023 · 8
- 2023GuidelineCancer of unknown primary, favourable subsetsGuideline ESMO Clinical Practice Guideline on cancer of unknown primary 2023: Axillary node adenocarcinoma in a woman
Treat as node-positive breast cancer: axillary dissection, breast radiotherapy or mastectomy, systemic therapy by receptor status.
- 2023GuidelineCancer of unknown primary, favourable subsetsGuideline ESMO Clinical Practice Guideline on cancer of unknown primary 2023: Cervical node squamous carcinoma
Treat as head and neck cancer: HPV and EBV testing, neck dissection or chemoradiotherapy with cisplatin.
- 2023GuidelineCancer of unknown primary, favourable subsetsGuideline ESMO Clinical Practice Guideline on cancer of unknown primary 2023: Midline poorly differentiated carcinoma in a young man
Treat as extragonadal germ cell tumour with cisplatin-based combination chemotherapy.
- 2023GuidelineCancer of unknown primary, favourable subsetsGuideline ESMO Clinical Practice Guideline on cancer of unknown primary 2023: Neuroendocrine carcinoma of unknown primary
Platinum-etoposide as for extrapulmonary neuroendocrine carcinoma; somatostatin analogues and radioligand therapy for well-differentiated tumours.
- 2023GuidelineCancer of unknown primary, favourable subsetsGuideline ESMO Clinical Practice Guideline on cancer of unknown primary 2023: Peritoneal serous carcinoma in a woman
Treat as advanced ovarian cancer: cytoreductive surgery and carboplatin-paclitaxel with maintenance as indicated.
- 2023GuidelineCancer of unknown primary, favourable subsetsGuideline ESMO Clinical Practice Guideline on cancer of unknown primary 2023: Single metastasis
Resection or stereotactic radiotherapy with curative intent.
- 2023GuidelineCancer of unknown primary, favourable subsetsGuideline ESMO Clinical Practice Guideline on cancer of unknown primary 2023: Work-up
Histology with directed immunohistochemistry, CT of chest, abdomen and pelvis, sex-specific examinations and tumour markers, PET-CT for cervical node squamous carcinoma and single-site disease.
- 2023MilestoneHistopathology & immunohistochemistryESMO guideline codifies the favourable subsets and their treatment
A milestone in how this cancer is treated.